Splash Pharmaceuticals Announces Dose Escalation in Phase I Clinical Trial in Platinum-resistant Ovarian Cancer Patients
- Category: Proteins and Peptides
- Published on Friday, 25 May 2018 10:45
- Hits: 2055
Clinical trial extends previous studies of SPL-108 in ovarian cancer
SAN DIEGO, CA, USA I May 24, 2018 I Splash Pharmaceuticals, Inc. (“Splash”), a closely held private biopharmaceutical company that develops novel cancer therapies, announced the successful completion of the first safety cohort of patients and initiation of dose escalation in its ongoing clinical trial in platinum-resistant ovarian cancer patients. The Phase I trial is being conducted at Rutgers Cancer Institute of New Jersey, a National Cancer Institute-designated Comprehensive Cancer Center.
SPL-108 has been examined in multiple Phase I and II clinical trials in over 100 human subjects with documented clinical activity and excellent safety and tolerability. SPL-108 has also demonstrated significant activity in animal models for a variety of cancers including ovarian, breast, endometrial, prostate, liver and brain. The current clinical trial is testing the safety and efficacy of SPL-108 in conjunction with paclitaxel in platinum-resistant ovarian cancer patients.
“The target, mechanism of action, and clinical data all support the idea of further testing SPL-108 and paclitaxel in ovarian cancer patients,” said Dr. David Nelson, President and CEO of Splash. “We believe that SPL-108 will be synergistic with other anti-tumor drugs as well and could be applicable in many different tumor types including breast and endometrial cancers. We are pleased that the first patients have cleared this critical safety hurdle.”
“Ovarian cancer is often first diagnosed in advanced stages and treated with platinum-based chemotherapy. For many patients, their disease will become resistant to this treatment. As a researcher, I am happy to have an opportunity to translate the discoveries in my laboratory and use SPL-108 in the clinic to further identify much needed therapy alternatives for this population,” said Dr. Lorna Rodriguez, Principal Investigator and Chief of the Gynecologic Oncology Program at Rutgers Cancer Institute.
About Splash Pharmaceuticals
Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is actively seeking Pharma partners to accelerate its novel clinical programs. For more information, visit www.splashpharma.com.
SOURCE: Splash Pharmaceuticals